Bromide

Bromide

SCHEMBL571256

Cn1cc[n+](CCC(=O)O)c1.[Br-]

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
HSP90AA1 P07900 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
EGLN3 Q9H6Z9 1/20 0.31
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717072 0.98 EGLN3 (0.32) MEN1KMT2AKDM4EPOLBHSP90AA1
Hydrochloric Acid SCHEMBL29008264 0.96 EGLN3 (0.34) MEN1KMT2AKDM4EPOLBHSP90AA1
SCHEMBL35213 0.87 LMNA (0.34) MEN1KMT2AKDM4EHSP90AA1SMN1; SMN2
Bromide SCHEMBL1977150 0.86 TSHR (0.39) MEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL6115678 0.86 TBXAS1 (0.36) MEN1KMT2AKDM4EHSP90AA1SMN1; SMN2
Bromide SCHEMBL6115295 0.85 MEN1 (0.40) MEN1KMT2AHSP90AA1SMN1; SMN2ALDH1A1
SCHEMBL18211781 0.84 TSHR (0.40) MEN1KMT2AALDH1A1
SCHEMBL22916707 0.84 TSHR (0.40) MEN1KMT2AALDH1A1
SCHEMBL18211773 0.84 TSHR (0.40) MEN1KMT2AALDH1A1
Glutarate SCHEMBL29142326 0.84 MEN1 (0.40) MEN1KMT2AHSP90AA1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9999217-B2 Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures BIOMATRICA, INC. (US) 2018-06-19 US claimed
US-9845489-B2 Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures BIOMATRICA, INC. (US) 2017-12-19 US claimed
EP-2598661-B1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES BIOMATRICA INC (US) 2017-09-27 EP claimed
EP-2598660-B1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES BIOMATRICA INC (US) 2017-03-15 EP claimed
US-20160338342-A1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES EXACT SCIENCES CORPORATION 2016-11-24 US claimed
US-20130209997-A1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES BIOMATRICA, INC. (US) 2013-08-15 US claimed
EP-2598661-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2013-06-05 EP claimed
EP-2598660-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2013-06-05 EP claimed
US-20120052572-A1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES EXACT SCIENCES CORPORATION 2012-03-01 US claimed
WO-2012018639-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES BIOMATRICA, INC. (US) 2012-02-09 WO claimed
WO-2012018638-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES BIOMATRICA, INC. (US) 2012-02-09 WO claimed
CN-115066207-B Method and system for menstrual group analysis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2026-05-26 CN disclosed
US-20220396836-A1 METHODS AND SYSTEMS FOR MENSTRUALOME ANALYSIS NEXTGEN JANE, INC. 2022-12-15 US disclosed
CN-115066207-A Method and system for menses group analysis 新生代吉恩公司 2022-09-16 CN disclosed
EP-4051127-A1 METHODS AND SYSTEMS FOR MENSTRUALOME ANALYSIS NextGen Jane, Inc. (US) 2022-09-07 EP disclosed
EP-2598661-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2013-06-05 EP disclosed
EP-2598660-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2013-06-05 EP disclosed
US-20120052572-A1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES EXACT SCIENCES CORPORATION 2012-03-01 US disclosed
WO-2012018639-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES BIOMATRICA, INC. (US) 2012-02-09 WO disclosed
WO-2012018638-A2 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES BIOMATRICA, INC. (US) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160338342-A1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES HNRNPD, HNRNPDL, HNRNPL MEN1 3064/4885KMT2A 3136/4885KDM4E 3252/4885
US-20120052572-A1 COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES HNRNPD, HNRNPDL, HNRNPL MEN1 3064/4885KMT2A 3136/4885KDM4E 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.